Cargando…
The future of intravenous iron in nephrology
Management of anaemia in chronic kidney disease (CKD) patients can be difficult and expensive. The recently completed Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT), the largest double-blinded trial of erythropoiesis-stimulating agents (ESA) treatment in CKD to date, provides us...
Autor principal: | Coyne, Daniel W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4813792/ https://www.ncbi.nlm.nih.gov/pubmed/27045558 http://dx.doi.org/10.1093/ndtplus/sfr040 |
Ejemplares similares
-
Pharmacokinetics and Pharmacodynamics of Oral and Intravenous Omadacycline
por: Rodvold, Keith A, et al.
Publicado: (2019) -
Pharmacokinetics and tolerability of lefamulin following intravenous and oral dosing
por: Wicha, Wolfgang W, et al.
Publicado: (2019) -
Current and future management approaches for rheumatoid arthritis
por: Breedveld, Ferdinand C
Publicado: (2002) -
Hydroxychloroquine in nephrology: current status and future directions
por: Rao, Indu Ramachandra, et al.
Publicado: (2023) -
Renin-Angiotensin Aldosterone System and Hypertension: Current Approaches and Future Directions
por: Flack, John M., et al.
Publicado: (2007)